Krebs Biochemicals and Industries liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

−2.36×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.09×	0.09×	0.10×	0.28×	0.33×
0.03×	0.03×	0.04×	0.12×	0.08×
0.1	0.1	0.1	0.1	0.1
−118	−103	−93.3	−44.4	−33.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

KREBSBIO₹57.93

Krebs Biochemicals and Industries Limited

· Pharma & Health

₹ CrorePeersALPA BALPHARMA VINEETLAB NATCAPSUQ BIOFILCHEM NECLIFE MANGALAM AAREYDRUGSMcap ₹125 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	-2.36
Current Ratio	0.33	0.28	0.10	0.09	0.09
Quick Ratio	0.08	0.12	0.04	0.03	0.03
Cash, Equiv & ST Investments	0.1	0.1	0.1	0.1	0.1
Working Capital	-33.0	-44.4	-93.3	-103.4	-118.2

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.